Company news

Tectonic Therapeutic, Inc. news in 2026

Tectonic Therapeutic, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Tectonic Therapeutic Announces Third Quarter 2026 Financial Results and Recent Business Highlights

November 5, 2026

Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)

September 29, 2026

Tectonic Therapeutic to Participate in the Morgan Stanley Global Healthcare Conference

September 3, 2026

Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights

August 6, 2026

Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients

June 9, 2026

Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights

May 7, 2026

Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors

April 23, 2026

TD Asset Management Inc. Announces TD ETF Distributions

March 19, 2026

Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

February 25, 2026

Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

February 23, 2026

Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026

February 11, 2026

Decks in 2026